Sei Investments Co. trimmed its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 7.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 170,337 shares of the biopharmaceutical company’s stock after selling 14,300 shares during the quarter. Sei Investments Co. owned 0.16% of Regeneron Pharmaceuticals worth $64,041,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Steward Partners Investment Advisory LLC increased its position in shares of Regeneron Pharmaceuticals by 495.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 307 shares during the last quarter. Vident Investment Advisory LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $200,000. Virtu KCG Holdings LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $206,000. AE Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $206,000. Finally, Moors & Cabot Inc. acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $217,000. 65.89% of the stock is owned by hedge funds and other institutional investors.
Several research firms have weighed in on REGN. BTIG Research reaffirmed a “buy” rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. BMO Capital Markets set a $444.00 target price on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Monday, November 27th. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $480.00 to $380.00 in a research report on Friday, December 1st. Cowen reaffirmed a “hold” rating and issued a $450.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 7th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, November 13th. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $463.19.
In other news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.80% of the company’s stock.
Regeneron Pharmaceuticals Inc (NASDAQ REGN) opened at $324.57 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18. The stock has a market capitalization of $36,816.13, a PE ratio of 31.45, a PEG ratio of 1.39 and a beta of 1.47. Regeneron Pharmaceuticals Inc has a 52 week low of $314.99 and a 52 week high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $1.05. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The business’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same quarter last year, the business posted $3.04 EPS. sell-side analysts expect that Regeneron Pharmaceuticals Inc will post 14.13 earnings per share for the current fiscal year.
WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/14/regeneron-pharmaceuticals-inc-regn-position-lessened-by-sei-investments-co.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.